WO2021054532A3 - 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물 - Google Patents

킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물 Download PDF

Info

Publication number
WO2021054532A3
WO2021054532A3 PCT/KR2019/017063 KR2019017063W WO2021054532A3 WO 2021054532 A3 WO2021054532 A3 WO 2021054532A3 KR 2019017063 W KR2019017063 W KR 2019017063W WO 2021054532 A3 WO2021054532 A3 WO 2021054532A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
efinaconazole
chelating agent
stabilized pharmaceutical
containing stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/017063
Other languages
English (en)
French (fr)
Other versions
WO2021054532A2 (ko
Inventor
김범준
구교탄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biobelief Co Ltd
Original Assignee
Biobelief Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biobelief Co Ltd filed Critical Biobelief Co Ltd
Publication of WO2021054532A2 publication Critical patent/WO2021054532A2/ko
Publication of WO2021054532A3 publication Critical patent/WO2021054532A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 특정 킬레이트화제를 포함하는 에피나코나졸-함유 용액 형태의 국소 투여용 약학 조성물을 제공한다. 본 발명의 약학 조성물은 우수한 물리화학적 안정성을 갖는다.
PCT/KR2019/017063 2019-09-17 2019-12-05 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물 Ceased WO2021054532A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190113967A KR20210032662A (ko) 2019-09-17 2019-09-17 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR10-2019-0113967 2019-09-17

Publications (2)

Publication Number Publication Date
WO2021054532A2 WO2021054532A2 (ko) 2021-03-25
WO2021054532A3 true WO2021054532A3 (ko) 2021-05-14

Family

ID=74884651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017063 Ceased WO2021054532A2 (ko) 2019-09-17 2019-12-05 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물

Country Status (2)

Country Link
KR (1) KR20210032662A (ko)
WO (1) WO2021054532A2 (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
KR20170102013A (ko) * 2015-01-12 2017-09-06 아르노 테라퓨틱스 인코포레이티드 진균류 감염을 억제하기 위한 조성물 및 방법
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
KR20170102013A (ko) * 2015-01-12 2017-09-06 아르노 테라퓨틱스 인코포레이티드 진균류 감염을 억제하기 위한 조성물 및 방법
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof

Also Published As

Publication number Publication date
KR20210032662A (ko) 2021-03-25
WO2021054532A2 (ko) 2021-03-25

Similar Documents

Publication Publication Date Title
PH12023550161A1 (en) Pharmaceutical composition and use thereof
ZA201902053B (en) Pharmaceutical composition
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
WO2018064119A8 (en) CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
ZA201902051B (en) Pharmaceutical composition
ZA201803678B (en) Pharmaceutical composition
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021010022A (es) Composicion farmaceutica.
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
ZA202006535B (en) Pharmaceutical composition comprising salbutamol
PH12021550901A1 (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
MX2020012989A (es) Agente terapeutico para la fibrosis.
PH12022551468A1 (en) Compounds active towards nuclear receptors
ZA201807446B (en) Improved drug formulations
ZA201902049B (en) Pharmaceutical composition
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
EP4606435A3 (en) Pharmaceutical composition comprising poorly soluble basic agent
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
EP3981389A4 (en) TOPICALLY ADMINISTRATED PHARMACEUTICAL COMPOSITION IN DISSOLVED FORM WITH EFINACONAZOLE
MX2019009235A (es) Compuestos antifibroticos.
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19946132

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19946132

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 13/09/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19946132

Country of ref document: EP

Kind code of ref document: A2